Conestoga Capital Advisors, LLC - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Conestoga Capital Advisors, LLC ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$17,328,716
-16.6%
254,572
+0.0%
0.30%
-9.7%
Q2 2023$20,775,406
+8.1%
254,507
-1.8%
0.33%
+2.5%
Q1 2023$19,219,290
-10.6%
259,055
-0.1%
0.32%
-19.9%
Q4 2022$21,497,000
+15.5%
259,375
+295.9%
0.40%
+10.4%
Q3 2022$18,606,000
-16.7%
65,515
+1.7%
0.36%
-10.3%
Q2 2022$22,330,000
-20.4%
64,419
-0.6%
0.41%
-4.0%
Q1 2022$28,069,000
-16.2%
64,819
+0.1%
0.42%
-3.0%
Q4 2021$33,495,000
-8.1%
64,744
-13.9%
0.44%
-13.5%
Q3 2021$36,434,000
+8.8%
75,189
+1.1%
0.50%
+4.1%
Q2 2021$33,474,000
+28.6%
74,343
+9.1%
0.48%
+23.5%
Q1 2021$26,035,000
-65.8%
68,168
-71.6%
0.39%
-67.7%
Q4 2020$76,135,000
-20.2%
239,757
-37.7%
1.21%
-37.0%
Q3 2020$95,389,000
-0.5%
385,051
+6.0%
1.92%
-7.9%
Q2 2020$95,885,000
+44.0%
363,104
+3.4%
2.09%
+7.2%
Q1 2020$66,581,000
-5.7%
351,128
+9.2%
1.95%
+14.7%
Q4 2019$70,601,000
+11.0%
321,632
-1.0%
1.70%
+4.4%
Q3 2019$63,593,000
-7.2%
324,999
-1.1%
1.63%
-5.0%
Q2 2019$68,506,000
+7.4%
328,584
+2.3%
1.71%
-3.6%
Q1 2019$63,800,000
+38.1%
321,328
+0.6%
1.78%
+20.7%
Q4 2018$46,206,000
-26.8%
319,277
+3.2%
1.47%
-8.6%
Q3 2018$63,128,000
+56.7%
309,282
+13.6%
1.61%
+24.2%
Q2 2018$40,297,000
+2.3%
272,367
+4.4%
1.30%
-14.0%
Q1 2018$39,387,000
+10.6%
260,772
-5.1%
1.51%
+10.3%
Q4 2017$35,603,000
+19.4%
274,822
+11.5%
1.37%
+3.6%
Q3 2017$29,809,000
-7.0%
246,582
-9.6%
1.32%
-20.9%
Q2 2017$32,057,000
+23.1%
272,828
+6.5%
1.67%
+6.0%
Q1 2017$26,044,000
+47.6%
256,213
+49.3%
1.57%
+34.0%
Q4 2016$17,650,000
-5.6%
171,644
+0.5%
1.18%
-8.3%
Q3 2016$18,696,000
+7.5%
170,744
+10.7%
1.28%
-0.3%
Q2 2016$17,395,000
+3.7%
154,249
-13.1%
1.28%
+13.3%
Q1 2016$16,781,000
+27.9%
177,544
+21.8%
1.13%
+7.0%
Q4 2015$13,116,000
-10.4%
145,735
-8.0%
1.06%
-9.7%
Q3 2015$14,643,000
-8.3%
158,369
-2.3%
1.17%
+6.0%
Q2 2015$15,964,000
-2.4%
162,120
-0.6%
1.11%
-1.1%
Q1 2015$16,357,000
+5.9%
163,099
-2.4%
1.12%
+4.3%
Q4 2014$15,440,000167,0951.07%
Other shareholders
BIO-TECHNE CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders